临床药师参与1例阿托伐他汀致肌病的药学实践

doi:10.3969/j.issn.1000-8535.2017.03.029

广州医药 ›› 2017, Vol. 48 ›› Issue (3): 109-111.DOI: 10.3969/j.issn.1000-8535.2017.03.029

• 个案分析 • 上一篇

临床药师参与1例阿托伐他汀致肌病的药学实践

刘金泳, 陈芳超, 朱秀梅

广州市第一人民医院南沙医院药学科(广州 511458)

收稿日期:2016-12-08 发布日期:2021-12-01

Clinical pharmacists participate in the pharmaceutical care: a case of atorvastatin-induced myopathy

LIU Jinyong, CHEN Fangchao, ZHU Xiumei

Department Of Pharmacy, Nansha Hospital of Guangzhou First People's Hospital, Guangzhou 511458,China

Received:2016-12-08 Published:2021-12-01

摘要/Abstract

摘要： 目的分析他汀致肌病的影响因素,使临床更加合理的使用他汀类药物,减少不良反应的发生。方法对1例口服阿托伐他汀钙片治疗5天后出现双大腿肌肉酸痛伴CK升高患者的病理生理因素、联合用药等情况进行分析,探讨他汀致肌病的相关因素及药学监护要点。结果临床药师判断他汀导致肌病可能性大,提出治疗建议和监护计划,促进了患者病情好转。结论他汀类药物导致肌病的影响因素较多,临床药师参与患者的临床治疗过程并加强药学监护,可促进药物治疗的安全性和有效性。

关键词: 他汀, 肌病, 临床药师, 药学监护

Abstract: Objective To analyze the influencing factors of myopathy caused by statins, to make the clinical use of statins more rational and reduce the incidence of adverse reactions. Methods The pathophysiologic factors and combined medication of patients with both thigh muscle soreness and CK increase after five days of oral atorvastatin calcium therapy were analyzed. The related factors of statin- induced myopathy and the points of pharmacy care were discussed. Results Clinical pharmacists determined the possibility of statin lead to myopathy, and put forward treatment recommendations and monitoring program to promote the patient's condition improved. Conclusion There are many influencing factors of myopathy caused by statins. Clinical pharmacists participate in the clinical treatment of patients and strengthen the medical care, which can promote the safety and effectiveness of drug treatment.

Key words: Statins, Myopathy, Clinical pharmacist, Pharmaceutical care

刘金泳, 陈芳超, 朱秀梅. 临床药师参与1例阿托伐他汀致肌病的药学实践[J]. 广州医药, 2017, 48(3): 109-111.

LIU Jinyong, CHEN Fangchao, ZHU Xiumei. Clinical pharmacists participate in the pharmaceutical care: a case of atorvastatin-induced myopathy[J]. Guangzhou Medical Journal, 2017, 48(3): 109-111.

参考文献

[1] 中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35:390-419.
[2] ZHANG H, PLUTZKY J, SKENTZOS S, et al. Discontinuation of statins in routine care settings: a cohort study[J]. Ann Intern Med,2013,158:526-534.
[3] FILIPPATOS T D, ELISAF M S. Safety considerations with fenofibrate/simvastatin combination[J]. Expert Opin Drug Saf,2015,14(9):1481-1493.
[4] 他汀类药物安全性评价工作组. 他汀类药物安全性评价专家共识[J]. 中华心血管病杂志,2014,42(11):279-293.
[5] BRUCKERT E, HAYEM G, DEJAGER S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study[J]. Cardiovasc Drugs Ther,2005,19:403-414.
[6] SAKAEDA T,KADOYAMA K,OKUNO Y,et al. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system[J]. Plos One,2011,6(12):e28124-e28124.
[7] HPS2-THRIVE COLLABORATIVE GROUP. Effects of extended-release niacin with laropiprant in high-risk patients[J]. N Engl J Med,2014,371(3):203-212.
[8] VOORA D,SHAH S H,SPASOJEVIC I,et al. TheSLCO1B1*5 genetic variant is associated with statin-induced side effects[J]. J Am CollCardiol,2009,54:1609-1616.
[9] SANTOS P C,GAGLIARDI A C,MINAME M H,et al.SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgiain Brazilian patients with familial hypercholesterolemia[J]. Eur J ClinPharmacol,2012,68:273-279.
[10] ROSENSON R S,BAKER S K,JACOBSON T A,et al. An assessment by the Statin Muscle Safety Task Force: 2014 update[J]. J ClinLipidol,2014,8(3):S58-71.
[11] ERIK S S,PAUL D T,ALBERTO C,et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management[J]. Eur Heart J,2015,36(17): 1012-1022.

临床药师参与1例阿托伐他汀致肌病的药学实践

Clinical pharmacists participate in the pharmaceutical care: a case of atorvastatin-induced myopathy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	何燕红, 许达亮, 徐进芳, 韩亚岩. 诺欣妥对扩张型心肌病心功能的效果观察[J]. 广州医药, 2021, 52(4): 117-119.
[2]	王俊奇, 顿驭光. 复方丹参滴丸联合阿托伐他汀治疗对伴有颈动脉粥样硬化短暂性脑缺血发作患者脑循环动力的影响[J]. 广州医药, 2021, 52(1): 105-108.
[3]	林雄方, 陈浩. 氟伐他汀联合环磷腺苷葡胺治疗慢性肺心病急性加重期疗效观察[J]. 广州医药, 2016, 47(3): 66-68.
[4]	叶漫湘, 何雪梅. 酒石酸美托洛尔联合辛伐他汀治疗心律失常的临床疗效分析[J]. 广州医药, 2015, 46(3): 72-74.
[5]	吴启文, 涂永生, 范绍翀, 张海良. RhoA-Rho激酶通路在鼻咽癌细胞的表达[J]. 广州医药, 2015, 46(2): 1-3.